The PerMel-AI project seeks to transform melanoma treatment, the most dangerous type of skin cancer, by using the Human Melanoma Proteome Atlas (HMPA) along with AI and machine learning. Our team of experts is focused on validating new drug targets and biomarkers to create personalized treatments. The HMPA includes detailed information from over 1,000 tumors, helping us identify precise biomarkers and targets for therapy. By using AI analyses, we aim to improve how patients are grouped and customize therapies based on each patient’s unique tumor characteristics. Our research tackles the complex nature of melanoma, where treatments can yield unpredictable results despite advancements in immunotherapy and targeted therapies. There is a critical need for reliable biomarkers and a clearer understanding of resistance to treatments. The PerMel-AI project plans to address these issues by utilizing AI and digital pathology to examine tumor differences at a single-cell level, enhancing accuracy in diagnosis and treatment planning. We also aim to meet significant medical and societal needs, such as the rising cases of melanoma in younger people and variations in disease symptoms. By developing effective biomarkers and drug targets, we can improve diagnostic procedures, refine treatment methods, and minimize guesswork in cancer care. Ultimately, the PerMel-AI project strives to advance melanoma treatment, improve patient outcomes, extend survival rates, and set new standards in oncology. Our approach leverages cutting-edge technologies and a diverse range of expertise to change how melanoma is managed and provide life-saving advancements to patients around the world.